PAVULON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PAVULON (PAVULON).
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, blocking transmission of nerve impulses to skeletal muscle.
| Metabolism | Primarily hydrolyzed by plasma pseudocholinesterase (butyrylcholinesterase); minor hepatic metabolism. |
| Excretion | Renal 80-100% as unchanged drug and metabolites; biliary/fecal negligible (<5%). |
| Half-life | Terminal elimination half-life 100-120 minutes in adults with normal renal function; prolonged in renal impairment. |
| Protein binding | Approximately 87% bound, primarily to albumin and gamma-globulins. |
| Volume of Distribution | Vd 0.25-0.3 L/kg, indicating limited extravascular distribution consistent with quaternary ammonium structure. |
| Bioavailability | Not applicable (administered IV only); oral bioavailability <5% due to poor absorption. |
| Onset of Action | IV: 3-5 minutes for intubating dose (0.08-0.1 mg/kg); faster onset with higher doses. |
| Duration of Action | Clinical duration (time to 25% recovery) 35-60 minutes after intubating dose; prolonged in renal failure or with volatile anesthetics. |
| Action Class | Skeletal muscle relaxant- Peripherally acting |
| Brand Substitutes | Panuron 2mg Injection, Pancuronium Bromide 2mg Injection |
0.04-0.1 mg/kg IV bolus for intubation; maintenance: 0.01-0.015 mg/kg IV every 25-60 minutes as needed or continuous IV infusion: 1-2 mcg/kg/min.
| Dosage form | INJECTABLE |
| Renal impairment | CrCl 10-50 mL/min: reduce dose by 25-50%; CrCl <10 mL/min: reduce dose by 50-75% and use with caution; prolonged effect possible. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75% or avoid; monitor for prolonged paralysis. |
| Pediatric use | Neonates: 0.02-0.04 mg/kg IV; Infants 1-12 months: 0.02-0.03 mg/kg IV; Children 1-12 years: 0.04-0.1 mg/kg IV; repeated doses at 25-60 min intervals as needed. |
| Geriatric use | Start at lower end of dosing range (0.04-0.06 mg/kg IV); monitor renal function and avoid if CrCl <30 mL/min; prolonged duration possible. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PAVULON (PAVULON).
| Breastfeeding | Pancuronium is poorly excreted into breast milk due to its high polarity and ionization at physiological pH. The milk-to-plasma ratio is estimated to be <0.1 based on physicochemical properties, but specific human data are lacking. Because oral bioavailability is negligible, systemic exposure to the nursing infant is minimal. The American Academy of Pediatrics considers pancuronium compatible with breastfeeding. However, monitor the infant for potential adverse effects such as muscle weakness or apnea, especially if high maternal doses are used. |
| Teratogenic Risk | Pancuronium is a quaternary ammonium compound with negligible placental transfer due to its polarity and high molecular weight. No teratogenic effects have been reported in animal studies at clinically relevant doses. In the first trimester, exposure is unlikely to cause congenital anomalies because pancuronium does not cross the placenta significantly. During the second and third trimesters, pancuronium can cross the placenta in limited amounts, but no fetal malformations have been associated. However, muscular relaxation in the fetus may occur if high maternal doses are given, potentially leading to neonatal hypotonia and respiratory depression at delivery. The overall risk of teratogenicity is low, but use should be reserved for situations where neuromuscular blockade is essential. |
■ FDA Black Box Warning
Should be administered only by experienced clinicians familiar with neuromuscular blocking agents. Facilities for intubation, artificial respiration, oxygen therapy, and reversal agents must be immediately available.
| Serious Effects |
Hypersensitivity to pancuronium or any component; use of depolarizing neuromuscular blocking agents (e.g., succinylcholine) may cause prolonged blockade.
| Precautions | Prolonged neuromuscular blockade may occur with renal or hepatic impairment; monitor neuromuscular function closely. Risk of histamine release causing hypotension and bronchospasm. Use caution in patients with myasthenia gravis, electrolyte disturbances, or those taking drugs that potentiate neuromuscular blockade. |
Loading safety data…
| Fetal Monitoring | Monitor maternal vital signs including heart rate, blood pressure, and oxygen saturation continuously during administration. Assess depth of neuromuscular blockade using peripheral nerve stimulator (train-of-four monitoring) to avoid excessive dosing. Observe for signs of histamine release (hypotension, tachycardia) and anaphylaxis. In pregnant patients, monitor fetal heart rate pattern continuously when feasible, especially during cesarean section. After administration, monitor for prolonged neuromuscular blockade, and assess recovery of muscle strength before extubation. In neonates, monitor for respiratory depression and hypotonia if pancuronium was used near delivery. |
| Fertility Effects | No direct effects on human fertility have been reported. Animal studies have not demonstrated impairment of fertility following pancuronium administration. As a nondepolarizing neuromuscular blocker, it does not alter hormonal balance or reproductive organ function. However, no specific fertility studies in humans are available. |